HC Wainwright Reaffirms Buy Rating for Cardiol Therapeutics (TSE:CRDL)

Cardiol Therapeutics (TSE:CRDL)‘s stock had its “buy” rating reiterated by analysts at HC Wainwright in a research report issued to clients and investors on Monday, BayStreet.CA reports.

Cardiol Therapeutics Trading Down 1.6 %

Cardiol Therapeutics stock traded down C$0.04 during mid-day trading on Monday, hitting C$2.43. The company’s stock had a trading volume of 51,566 shares, compared to its average volume of 137,464. The company has a 50 day moving average of C$2.24 and a 200-day moving average of C$1.59. The stock has a market cap of C$158.22 million, a PE ratio of -5.58 and a beta of 0.75. The company has a debt-to-equity ratio of 0.52, a quick ratio of 6.84 and a current ratio of 5.29. Cardiol Therapeutics has a one year low of C$0.74 and a one year high of C$2.94.

Cardiol Therapeutics Company Profile

Cardiol Therapeutics Inc, a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of cardiovascular disease (CVD). Its lead product CardiolRx, which is in Phase II/III multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx for patients hospitalized with COVID-19, as well as for the treatment of recurrent pericarditis and acute myocarditis.